HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells.

AbstractBACKGROUND:
Tumor suppressor genes encode critical cell cycle regulatory proteins that are frequently mutated or deleted in cancer and, therefore, are important candidates for cancer treatment based on gene replacement strategies.
MATERIALS AND METHODS:
We evaluated and compared the relative potential therapeutic efficacy of p14ARF and p16INK4A expressed in adenoviral vectors (Adp14ARF and Adp16INK4A, respectively) in three human mesothelioma cell lines.
RESULTS:
The cytotoxic effects of expressed p16INK4A were significantly greater than that of p14ARF in both H28 and H2052 cells. Cell cycle G1 arrest occurred earlier with Adp16INK4A treatment than Adp14ARF (24 hours vs. 48 hours, respectively). Although both Adp14ARF and Adp16INK4A inhibited cell proliferation significantly and were potentiated by chemotherapy, Adp16INK4A appeared more potent.
CONCLUSION:
Our results suggest that adenoviral gene-based therapy, especially using Adp16INK4A-based strategy, may be effective in the treatment of human mesothelioma.
AuthorsCheng-Ta Yang, Liang You, Yu-Chin Lin, Chun-Liang Lin, Frank Mccormick, David M Jablons
JournalAnticancer research (Anticancer Res) 2003 Jan-Feb Vol. 23 Issue 1A Pg. 33-8 ISSN: 0250-7005 [Print] Greece
PMID12680192 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Cyclin-Dependent Kinase Inhibitor p16
  • Tumor Suppressor Protein p14ARF
  • Tumor Suppressor Protein p53
  • Paclitaxel
  • Cisplatin
Topics
  • Adenoviridae (genetics)
  • Antineoplastic Agents (pharmacology)
  • Cell Cycle (genetics)
  • Cisplatin (pharmacology)
  • Combined Modality Therapy
  • Cyclin-Dependent Kinase Inhibitor p16 (biosynthesis, genetics)
  • Genetic Therapy (methods)
  • Genetic Vectors (genetics)
  • Humans
  • Mesothelioma (drug therapy, genetics, metabolism, therapy)
  • Paclitaxel (pharmacology)
  • Tumor Cells, Cultured
  • Tumor Suppressor Protein p14ARF (biosynthesis, genetics)
  • Tumor Suppressor Protein p53 (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: